Research
Hormonal
SGLT2 receptor inhibitors (SGLT2R-i) provide significant cardiovascular and renal benefits, including reduced cardiovascular mortality and heart failure hospitalization, in addition to glycaemic control, by preventing glucose reabsorption in the kidneys.
SGLT2 inhibitors (like empagliflozin or dapagliflozin) are powerful drugs for T2DM patients with heart or kidney risks. They significantly reduce heart failure hospitalizations and mortality. Maintain good hygiene to minimize the risk of genital infections.
StrongSupportsVERY_HIGH confidence
They gained prominence when the EMPA-Reg trial in 2015, using empagliflozin with standard care in patients with T2DM at high risk of cardiovascular events, showed a relative risk reduction (RRR) of 38% in cardiovascular mortality, 35% RRR in heart failure hospitalisation (HFH) and 32% RRR in all-cause mortality
Why this rating
Supported by major trials (EMPA-Reg, DECLARE-TIMI 58, DAPA-HF, EMPEROR Reduced).
Source
Management of Type 2 Diabetes Mellitus
Leslie Bahn Kawa · IntechOpen eBooks · 2023
DOI 10.5772/intechopen.1002478
book_chapterCited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Metformin is the first-line pharmacological treatment for T2DM and prediabetes, offering significant reduction in microvascular complications and diabetes-related deaths through mechanisms including inhibition of hepatic gluconeogenesis and increased insulin sensitivity.Strong
- Supervised combined exercise and dietary interventions significantly improve glycaemic control, comorbidities, and quality of life in Type 2 Diabetes Mellitus (T2DM) patients, with supervised exercise yielding superior outcomes to unsupervised regimens.Good
- GLP-1 receptor agonists (GLP1-RA), particularly long-acting formulations, provide superior glycaemic control, weight loss, and cardiovascular risk reduction compared to short-acting GLP1-RA, and are recommended for chronic weight management and MACE reduction.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →